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Abstract
Topic: Chapter discussing the indications for treatment of brain aneurysms, 
endovascular techniques, tips and tricks. 1. Pathophysiology of aneurysms: 
Discuss the formation of aneurysms, current thinking of aneurysm development 
2. Prevalence/Incidence of aneurysms: Discussion of current state of aneurysm 
prevalence and how it differs in different populations 3. Unruptured Aneurysms: 
Diagnosis, Management and Treatment: Imaging paradigms of brain aneurysms, 
current thoughts on how to follow aneurysms which are being observed, different 
treatment options for unruptured aneurysms, including clipping, coiling, stent 
assisted coiling, flow diverter stent, flow disruptors, including the medical manage-
ment of stent placement 4. Ruptured Aneurysms: Diagnosis, Management and 
Treatment: Imaging paradigms of ruptured aneurysms, management options for 
co-morbidities associated with aneurysm rupture, treatment options including coil-
ing, clipping, flow diverter stents, flow disruptors 5. Complication Avoidance: Tips 
and tricks to avoid complications in the treatment of brain aneurysms.
Keywords: brain aneurysms, subarachnoid hemorrhage, coils, flow diversion,  
flow disruption
1. Pathophysiology of aneurysms
A cerebral aneurysm is defined as a local outpouching of an intracranial 
artery and can either be saccular or fusiform. The formation of aneurysms is an 
incompletely understood gradual process [1] involving genetics, epidemiology and 
pathobiology, in conjugation with the study of biophysics provides a more complete 
picture on how these factors interact [2]. The natural history of saccular intracra-
nial aneurysms consists of three phases: initiation, growth, and either stabilization 
or rupture, and the application of scientific principles to biological processes has 
made it easier to understand the behavior of aneurysm formation and rupture.
1.1 Genetic factors
Various genome studies and subsequent replication case control studies suggest 
genetic components in the formation of intracranial aneurysms (IA), no specific 
genes strongly associated with formation have yet been identified. A meta-analysis 
[3], identified three single nucleotide polymorphisms (SNPs) located on chromo-
some 9 within the CDKN2B-AS1 gene, on chromosome 8 near the SOX17 transcrip-
tion regulator gene, and on chromosome 4 near the endothelin receptor gene 
associated with the presence of sporadic IAs. A new IA susceptibility locus on 13q 
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was identified [4]. Subsequent genome-wide association studies [5, 6] have found 
additional loci on chromosome 7 near HDAC9, as well as in chromosomal regions 
1p34.3–p36.13, 19q13.3, Xp22 and 7q11. The strongest evidence for linkage was with 
a locus on 7q11 near the perlecan gene that encodes elastin, a protein that is involved 
in the preservation of vessel wall integrity.
1.2 Structural changes and hemodynamics
Cerebral arteries are prone to aneurysm formation due to presence of cerebro-
spinal fluid, sparse tunica adventitia, lower proportion of elastic fibers and disrup-
tion of internal lamina at bifurcation [7–9]. Blood is an active participant in the 
formation of aneurysms, its flow provides the mechanical triggers for reactions in 
the vessels at the level of the endothelium, while it is also a biological participant in 
the inflammatory cascade [10, 11]. This dual function of blood contributes signifi-
cantly to the degradation of the arterial wall in the formation of aneurysms [2].
Cohort studies on people with a familial preponderance to saccular aneurysm have 
shown that the geometry of bifurcations around the circle of Willis adds additional 
stress to the vessel walls, given the significant shifts in flow velocity, dynamic forces, 
and shear stress. Thus, high flow across a wall that is not “designed” for the exposed 
pressures results in tissue injury and remodeling. The biological result may be plaque 
or may be an aneurysm, depending on the presence (or absence) of an intact media 
[2]. Fluid-dynamic models calculate and visualize wall shear stress or wall shear 
gradients, intra-aneurysmal flow, impingement zones, and flow patterns or velocities. 
Wall shear stress constitutes the degree of friction in the intracranial aneurysm wall 
that results from blood inflow and impingement into the aneurysm. High and low 
wall shear stress can both be present during aneurysm formation but the relevance of 
these flow conditions to the pathogenesis, growth and rupture of an aneurysm remain 
unclear [12]. The role of shear stress is very controversial, responsible for damage at 
specific phases of aneurysmal development and rupture. Some studies suggest the 
direct effect of shear stress on the vessel wall resulting in injury and degeneration of 
the wall’s media, leading to aneurysm formation. Others suggest that low shear stress 
in the aneurysm and the vessel wall may result in small thrombus formation, endo-
thelial reactivity, and inflammation at the site, thus weakening the vessel.
Data generated from fluid-dynamic models could help improve our understand-
ing of aneurysm formation patterns and potential structural deficiencies in aneu-
rysms. The relevance of existing data derived from computational fluid modeling 
is limited, however, because the majority of studies compared ruptured with 
unruptured aneurysms. An ideal approach would be to compare the same aneurysm 
before and after rupture [13–16].
1.3 Molecular changes
In response to internal elastic lamina disruption and the subsequent mechanical 
overload and shift in tensile forces, vascular smooth muscle cells and fibroblasts 
synthesize collagen types I and V, which are the main molecular constituents of 
intracranial aneurysms [17].
Once the molecular mechanisms fail to compensate for the mechanical overload 
of the vessel wall and myo-intimal injury, cellular and humoral inflammatory 
responses become the main drivers of aneurysm formation [17–20]. These responses 
are mediated by inflammatory cytokines such as tumor necrosis factor (TNF), 
IL-1β and matrix metalloproteinases (MMPs), promote influx of macrophages and 
continuous degradation of collagen and elastin fibers. Wall shear stress might also 
contribute to cellular inflammatory responses during aneurysm formation.
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1.4 Can aneurysm rupture be predicted?
Aneurysm rupture has been suggested to occur as aneurysm expansion 
approaches and exceeds the physical limits of the tissue. It has also been suggested 
that the vibrations induced by pulsatile flow and the subsequent resonant frequency 
may promote aneurysmal rupture [21, 22]. Although not directly resulting in 
aneurysmal rupture, vibrational irregularities secondary to the presence of the 
aneurysm may accelerate the degeneration of the aneurysmal wall and subsequently 
lead to rupture. A shift to quantitative and not just qualitative analysis, and a focus 
on flow and flow dynamics as a force of influence in rupture have changed the 
landscape of research for cerebral aneurysms [2].
2. Prevalence and incidence of aneurysms
Although Unruptured Intracranial Aneurysms (UIA) are common [23, 24]. 
Their prevalence is subject to changes due to the improvements in invasive and non-
invasive imaging techniques, the increasing knowledge about the related factors 
that determines screening in asymptomatic populations and the increase in the life 
expectancy. Historically, the methods used to address prevalence were retrospec-
tive or prospective autopsy studies in the decades from 1950’s to the earliest 2000’s 
[25] but non-invasive imaging studies have demonstrated higher prevalence and 
prevalence ratios compared to autopsy studies (PR 3•5, 95% CI 2•1–6•1)3. To study 
UIA, the Magnetic Resonance Angiography (MRA) is the most common method 
for detection in asymptomatic patients [26] and compared to Intra-Arterial Digital 
Subtraction Angiography (IA-DSA), systematic reviews have found no significant 
differences in the prevalence reported between these two imaging techniques 
(more details will be elucidated in the next section of this chapter). However, it’s 
important to highlight that prevalence reported in non-invasive imaging studies 
can present limitations due to the interobserver agreement, training, experience, 
quality of equipment and expert’s judgment [27].
The IA characteristics are also a major concern in prevalence studies; technical 
limitations in regard to location, size and morphology can decrease the sensitiv-
ity and specificity of the diagnostic methods. Both, large and relatively small [28] 
cohort’s studies had shown that saccular morphology is the most common form of 
presentation and that among patients without history of subarachnoid hemorrhage 
(SAH) the distribution of IA in the internal carotid artery (ICA) and middle cerebral 
artery (MCA) are 24.8 and 22.7% [29] respectively, however in patients with previous 
history of SAH, the prevalence is higher in the MCA. In regard to the size, modern 
imaging techniques can easily detect aneurysms from 2 mm, which is extremely 
important to determine the risks of possible treatments or natural history, so far, the 
current evidence is that UIA > 5 mm, location in basilar artery apex and decrease in 
BMI over the follow-up period are related to speed up the 2.9% of aneurysm growth 
per year. However, irrespective of aneurysm size, the irregular shape and daughter sac 
are more likely to rupture [30, 31]. Although we know these are contributing factors, 
there is still a need to understand better the contribution of aneurysm related factors.
The prevalence of UIA among the general population is 3–5% [32] but there are 
several differences between populations that increase the risk for having a IA or a 
SAH. The risk factors commonly associated to IA development and rupture whether 
there’s a previous history of SAH or not, are age > 30, female sex, African-American 
race, smoking, alcoholism, hypercholesterolemia, high blood pressure, first and 
second-degree relatives with SAH history, and other comorbidities as polycystic 
kidney disease, connective tissue disorders and brain tumors [33–36]. However, 
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lifelong follow-up studies of UIA suggested that only female sex and smoking status 
were significant risk factors for aSAH [37]. Across countries, compared to USA 
prevalence, China, Japan, European countries including (UK, Netherlands, Finland, 
Germany and Italy) had no significant differences in the prevalence ratios adjusted 
to age, sex and comorbidities [38–41]. Other studies in Iranian population [42] have 
shown a prevalence of 3.2% but more studies in non-Caucasian populations are still 
required to further understand the impact of genetics and cultural practices.
The incidence of aneurysmal SAH (aSAH) reports are questionable, first, in 
average 20% of the aSAH deaths occur suddenly, away from hospital or in emer-
gency rooms [43]. Therefore, incidence can vary between countries with different 
autopsy rates and medical study protocols. In the case of Finland, the PHASES 
study showed a 3–6 times increased risk of aneurysm rupture in compared to other 
European nations and USA [44]. However, these findings can be a proof of how 
epidemiological studies need to improve their parameters more than a proof that 
Finnish people have more risk of aSAH. Finland has high rates of autopsy studies in 
sudden deaths [45] and all nonhospital deaths and moreover, longer life expectancy 
and pyramid shrinking due to the increasing of elderly population [46]. So, there’s 
no currently strong evidence to conclude that aSAH in Finland cohorts is truly 
higher than the other countries included in the PHASES study.
In spite of this evidence, careful consideration must be taken when we think 
about the pros and cons to treat a patient based on their personal risk factors. Most 
of the large cohort’s publications and meta-analysis have been done in popula-
tions where ethnicity diversity was limited, the impact of social stratus had not 
been assessed and criteria for collecting data and analysis was not standardized. 
Therefore, perfect epidemiological studies do not exist so, great efforts will be nec-
essary to determine inclusion and exclusion criteria in future prospective cohorts.
3. Unruptured intracranial aneurysms
Diagnosis of unruptured intracranial aneurysms (UIA) in most of the cases is 
incidentally during evaluations of other conditions [44] because the vast majority 
are asymptomatic or have subtle manifestations. Only, 10 to 15.5% of patients have 
symptoms related to UIA [45]. These symptoms generally are associated to mass 
effect due to the aneurysm size and growth, rarely cranial neuropathy or even more 
rare with sentinel hemorrhage, due to minimal blood leaking with the consequent 
meningeal irritation [45]. Symptomatic UIA often present with neurological deficits 
as visual dysfunction, ocular nerve palsy, bilateral temporal hemianopsia and other 
neurological symptoms as headaches, embolic cerebral ischemia, poorly defined 
spells, and seizures [46, 47]. Patients with symptomatic UIA need more attention 
because this can be a manifestation about riskier distribution and morphological 
[45] characteristics of the aneurysm, and a warning sign of an impending rupture 
[48]. The diagnoses modality after incidental discovery of an UIA, is based on 
which imaging modality is more sensitive depending on aneurysms characteristics, 
patients related factors, medical history and moreover, methods available in each 
center. Therefore, there is no specific diagnoses algorithm for UIA. The decision 
of screening or further imaging after finding an incidental aneurysm is still on the 
specialist judgment. These considerations are discussed below:
It has been mentioned that most of the UIA are diagnosed incidentally, and some 
of the non-invasive imaging methods have also been mentioned in the “prevalence” 
section of this chapter. However, there are still different evidences about the rates of 
diagnosis and prevalence reported through these non-invasive imaging methods as 
the MRA or CTA and IA-DSA, the current gold standard [22, 49]. Many authors had 
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suggested that the MRA and CTA to be the best methods for preliminary screen-
ing of IA [50, 51], the sensitivity and specificity of both methods are 87 and 95% 
for MRA and 90 and 86% for CTA [47]. But the effectiveness of the diagnoses can 
decrease depending on the IA characteristics; in UIA < 3 mm, MRA and CTA sensi-
tivity plummet to 38 and 61%, respectively [52]. Moreover, the high rates of comor-
bidities in people with UIA product of common pathophysiology (like hypertension 
with the consequent kidney failure) or to the old age of patients can limit the use 
of the contrast dye in CTA for screening. Therefore, MRA is the most frequent tool 
for screening nowadays. Other non-invasive techniques like transcranial Doppler 
(TCD) have been explored, but whether power Doppler is done with or without 
contrast enhancement, it’s sensitivity and specificity together are not superior to 
MRA and CTA [51]. Nevertheless, TCD can be a screening tool in countries were the 
expensive costs of MRA or CTA makes them inaccessible.
Sensitivity and specificity of imaging methods for diagnostic are important, but 
more considerations should be taken to study UIA characteristics. IADSA, provides 
the better spatial resolution than other techniques [44], but this method may not 
provide a good sense of aneurysm volume and can present difficulties when vessels 
are overlapped, and therefore 3D reconstructions are often needed to fully evaluated 
for intracranial aneurysms. Moreover, IADSA as an invasive method, can carry risks; 
2.3% of patients can present transient neurological complications, 0.4% permanent 
neurological complications and 14.7% of non-neurological complications [52]. Novel 
imaging methods as the Optical coherence tomography (OCT) can be useful to assess 
key factors in aneurysm structure due to the power to increase 10 times image resolu-
tion compared to other current techniques [44] and furthermore, OCT has a nearly-
biopsy resolution [53] and enhance resolution of birefringent tissues as artery laminas 
[54] which is major concern in pathophysiology, as mentioned before in this chapter.
Furthermore, considerations need to be taken as to imaging modality if the 
patient has had previously treated aneurysms. MRA is not sensitive for patients 
with previously treated clipped aneurysms. For these patients CTA is preferred. 
MRA is still sensitive for previously coiled aneurysms. For patients treated with 
flow diverter stents either MRA with contrast or CTA can be used. If the patient had 
coils with any kind of stent, then MRA with contrast is the preferred modality.
Taken together the results of imaging for UIA, the neuro-interventional team 
consider the possible treatments for each patient based on the risks and benefits 
between prevent treatment and natural history, however due to lack of evidence 
of the natural history in some categories of UIA is not uncommon to balance the 
pros and cos between prevent treatment and aSAH outcomes. Some of the current 
available treatments will be discussed below.
3.1 Conservative management
First of all, having an aneurysm does not imply always the need to undergo 
surgical or endovascular treatment. Most of the UIA will never cause symptoms 
neither rupture or at least the probability of this events will not be over 1% per year. 
Therefore, many patients decide to take the risk of conservative management over 
the risks of preventive treatments. However, conservative management is not equal 
to doing nothing, this management bear intervention from the physician to educate 
well the patient about the risk factors that will increase the probabilities of rupture 
and an active participation of the patients to modify their risky habits. There is 
strong evidence that supports the conservative management when lifetime risk of 
morbidity and mortality is low [42] as represented in Figure 1.
Nevertheless, in patients under conservative management, imaging follow-ups at 
1 year intervals have been recommended with CTA or MRA [25] to assess aneurysm 
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growth, although it is unclear whether this frequency of time-interval is truly 
necessary. However, is not uncommon to have mixed factors in UIA patients, to make 
it clear, a systematic review showed that if hypertension and history of SAH are pres-
ent (considering this both as major risk factors) in a patient under 70 years, with an 
<10 mm UIA in the anterior circulation, we will still be talking about a probability of 
risk of ~1% per year [24]. So, a standardized timing for imaging follow-ups accord-
ing to each patients and aneurysm related factors does not exist, in part because 
aneurysm growing is discontinuous but the ELAPSS score (mentioned in Figure 1) 
can be helpful to determine the need of follow-up at 3 or 5 years based on the risk 
of aneurysm growth [55]. These patients who choose conservative management live 
with a small very definite risk of rupture. Recently, a study showed that patients 
with untreated UIA, may decrease their quality of life (QoL) and moreover, trigger 
mental disorder as anxiety and depression [56, 57] possibly due to the uncertainty of 
whether their aneurysm is going to burst and when.
3.2 Surgical management
Successful surgery is achieved in most of the cases by excluding aneurysms from 
circulation but currently, there is a lack of prospective, multicenter and randomized 
Figure 1. 
Giant right vertebral aneurysm before and after coiling.
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trials that report outcomes in a uniform way. Moreover, most of the studies were done in 
patients with previous aSAH like the ISAT trial [58], which makes difficult to extrapo-
late those results to patients with UIA and no history of aSAH. The ISUIA-2 study 
did evaluate the surgical outcomes of nearly 1500 patients. They reported a mortality 
rate of 2.7% at 1 year and poor outcome (mRS 3–5) of 1.4% at 1 year. In this study, 
age > 70, posterior circulation and giant aneurysms were all associated with higher 
surgical morbidity and mortality. A meta-analysis done in the US with patients without 
previous history of aSAH that underwent to elective surgical clipping (SC) 14,411 and 
to endovascular treatment (EVT) 16,659 reported that iatrogenic stroke, intracranial 
hemorrhage, pulmonary complications, sepsis and status epilepticus were significantly 
higher after SC [59]. Moreover, the reduced recovery time and shorter stays in hospital 
[60] play a major role in the final decision of patient to avoid surgery. Nowadays, SC is 
usually reserved to younger patients that will benefit more from an immediate occlusion 
of the aneurysm, less need to have follow-up imaging, less probability of retreatment 
and the ones with large and giant aneurysms or locations in the MCA.
3.3 Endovascular treatment (EVT)
Since its conception, endovascular treatment has rapidly taken over as the 
major treatment for most intracranial aneurysms. While there is supporting data 
for ruptured intracranial aneurysms from the ISAT trial, there is no randomized 
controlled trial comparing surgery and endovascular treatment to surgical clipping 
for unruptured aneurysms. Relative indications for endovascular treatment are poor 
surgical candidate, favorable aneurysm and vascular anatomy, high risk for anesthe-
sia complications and posterior circulation aneurysms. In 2012, a systematic review 
and meta-analysis reported different outcomes between endovascular treatments; 
>52 years, >10 mm and posterior circulation location were main risk factors to poor 
outcomes [61]. Coiling alone was safer compared to the percent of complications 
reported with balloon-assisted coiling 7.1% (99% CI 3.9–12.7), 9.3% (99% CI 4.9–
16.9) with stent-assisted coiling and 11.5% (99% CI 4.9–24.6) with flow-diverting 
stents. However, the increase of the complications reported with additional devices 
can be due to the more-complex aneurysm cases or due to the number and type of 
devices placed. Furthermore, in the last decade the neuro-interventional procedures 
have improved their outcomes with increased understanding of the various treat-
ments and technological innovation improving safety and efficacy.
3.4 Coiling
EVT emerged in the 1990’s with coiling [62]. Since then, technological advances 
in coil properties made neuro-interventional procedures safer with improved out-
comes. Recently, a single center study reported 0% of poor outcomes when coiling 
was used [25], however >20% of poor outcomes have been reported after coiling in 
aneurysms >10 mm size, with wide necks, unfavorable dome-to-neck ratio < 2 and 
fusiform configuration [63]. So, using coiling alone must be used just in aneurysms 
with specific characteristics, otherwise new devices must be considered.
3.5 Stent assisted coiling
This method represents a solution for aneurysms in which coiling alone will not 
be the best option (mentioned in Figure 1), as coiling this endovascular technique 
has the same concerns about patient selection, recovery and risks. However, when 
leaving a stent placed in the artery it is important to manage the tolerance and 
adherence of the patient to dual anti-platelet therapy (DAPT) (Figure 2)[64].
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3.6 Flow diversion
This method was developed in the 2000s. The concept of Flow Diversion is that 
a high-mesh density stent placed in the parent artery will disrupts blood flow into 
the aneurysm with the subsequent thrombosis of the aneurysm, this process takes 
6 weeks to 6 months in average in radiographic follow-ups. Moreover, the stent in 
parent artery provides a scaffold for which endothelium can grow [62]. In 2011, the 
FDA approved the Pipeline Embolization Device (PED) for large or giant (≥10 mm) 
wide-necked intracranial aneurysms from the petrous to the superior hypophyseal 
segments of the ICA [65]. Since then, a second flow diverter stent (Surpass) has 
come to market. Flow diverter stents now have expanded indications, including 
smaller aneurysms, and aneurysm up to the internal carotid artery bifurcation. 
Recently, a multicenter group published a retrospective study of follow-ups 
after PED placement [66], in this report overall complications were 3.4% and in 
multivariate analysis older age > 70, larger diameter > 15 mm and fusiform were 
identified as independent variables with higher rates of incomplete occlusion in 
6-month follow-up. However, currently there is not a standardized scale to report 
Figure 2. 
Pipeline placement in a wide neck aneurysm in the left vertebral artery.
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radiographic outcomes that can be useful to meta-analysis studies or to new pro-
spective randomized cohorts. Flow diverter stents are currently also limited usually 
to unruptured aneurysms, given the need for DAPT, however their use has found a 
niche in the treatment of ruptured blister aneurysms. Consequently, the next gener-
ation of this technology is looking into the possibility of special coating to mitigate 
the need for DAPT. Further investigation is still needed before this advancement 
will come to market.
3.7 Flow disruptors and web endoluminal bridge (WEB)
Although flow diversion devices can work out for many types of aneurysms as 
off-label uses; aneurysms located in bifurcations with wide neck and dome-to-neck 
ratio > 1 and < 2 remains a challenge for this technology. Therefore, the WEB device 
was created in regard of these concerns in flow diversion and has proven promising 
to overcome those limitations. The WEB device is placed intra-aneurysm with a 
subsequent change in the blood flow at the aneurysm neck [67]. In European multi-
center prospective studies, the WEB device placed in basilar, MCA, Acomm and ICA 
bifurcation showed 2.7% of morbidity and at 1 year of follow-up, 56% of aneurysm 
complete occlusion [68]. Owing this method does not require to put the patient 
under DAPT unlike the PED, it can be used also in aSAH cases. Further investigation 
is needed as to the long-term outcomes for this device (Figures 3 and 4).
3.8 Medical management after flow diverter placement
All the patients that can be good candidates for PED placement based on their 
UIA characteristics needs also to be eligible for prolonged DAPT. Acetylsalicylic 
acid (ASA) plus clopidogrel is the DAPT of reference used for preventing thrombo-
sis in such procedures [69]. The laboratory tests pre and post-procedure are yet to 
be standardized; due to the risk of clopidogrel resistant (28–68%) [70], is has been 
considered necessary to assess platelet reactivity. High platelet reactivity (HPR) 
is related with thromboembolic evens after stenting arteries [71]. Depending on 
institutional protocols, some neuro-interventional teams use the VerifyNow P2Y12 
assay which has been widely studied however, the results of this tests may not be 
completely reliable [72] due to the fact that P2Y12 response units (PRU) cannot dif-
ferentiate aspirin-induced platelet inhibition in patients administered clopidogrel. 
Other studies recommend the use of the Thromboelastography (TEG), which is 
dynamic and real time tool to measure clot formation. The advantages of VerifyNow 
assay is that can be done very fast with instant results, however in patients with 
programed procedures for UIA stenting this concerning may not be transcendental.
Figure 3. 
Web Endoluminal bridge placement in left ICA bifurcation.
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VerifyNow can overestimate the rate of clopidogrel resistance when compared to 
TEG. However, there is currently no randomized trials that have assessed the utility 
of this tests. Moreover, there’s no strong evidence to support that the assessment 
of platelet reactivity improves clinical and imaging outcomes after stent place-
ment. Nevertheless, the neuro-interventional teams at these days usually starts the 
DAPT with 325 mg of ASA and 75 mg of clopidogrel 7 days prior and maintain for 
3–6 months after PED placement.
4. Ruptured intracranial aneurysms
A 50-year-old female was preparing her children for school when she experi-
enced a headache severe enough to make her lie down on the sofa. She managed 
to get the children off to school, but the headache did not abate. She was used to 
headaches, as she had migraines periodically that were controlled with over-the-
counter medications, but this one was different and much more intense. She took a 
couple of acetaminophen, and when the pain was not relieved, she brought herself 
to the emergency department (ED) [73].
Headache is seen in up to 2% of patients, presenting to the emergency department 
(ED). Most are benign, but it is imperative to understand and discern the life-threat-
ening causes of headache when they present. Headache caused by a subarachnoid 
hematoma (SAH) from a ruptured aneurysm is one of the deadliest, but fortunately, 
also rare, comprising only 1% of all headaches presenting to the ED [74].
Rupture is the most serious consequence of intracranial aneurysms. 
Subarachnoid hemorrhage (SAH) from a leaking aneurysm is a neurological 
emergency. While SAH is typical of aneurysmal rupture, it is also associated with 
intraventricular hemorrhage, intracerebral hemorrhage, and subdural hematoma. 
The force of rupture and location of an aneurysm determine the presence of the 
other types of hemorrhage. Although the prevalence of aneurysms is high, the 
Figure 4. 
Flowchart of management after incidental UIA diagnosis.
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global annual incidence of subarachnoid hemorrhage is 10/100,000person years, 
so the best possible treatment plan would be to determine exactly those aneurysms 
that will rupture and the ones that never will.
4.1 Presentation
The presenting symptom of SAH is acute headache, generally described as “the 
worst headache of my life.”
Some cohort studies mention it as “thunderclap” headache that peaks at head-
ache onset or reaches severity within minutes to an hour of onset [75].
1. Signs of meningeal irritation-meningismus, photophobia
2. Signs of intracranial hypertension-nausea, vomiting, diminished level of 
consciousness
3. Epileptic seizures
4. Focal neurological deficits
5. Intraocular hemorrhage [76, 77]
• Terson syndrome: hemorrhage in vitreous humor, associated with high 
mortality [78]
• Subhyaloid (pre-retinal) hemorrhage [79].
4.2 Scoring system
Several scoring systems have been developed to predict patient outcomes 
for those with aneurysm related sub-arachnoid hemorrhage (a-SAH). The Hunt 
and Hess score and World Federation of Neurological Surgeons grading system 
are both used to predict patient outcome, and the Fisher grade helps to predict 
vasospasm [80, 81].
The severity of neurologic impairment and the amount of subarachnoid bleed-
ing on admission are the strongest predictors of neurologic complications and 
outcome [82]. Therefore, it is essential that patients with SAH be scored promptly 
after arrival and stabilization. The World Federation of Neurological Surgeons Scale 
(WFNSS) and the modified Fisher Scale are the most reliable and simple to perform 
[74, 75]. Higher WFNSS and modified Fisher Scale scores are associated with worse 
clinical outcome and a higher proportion of neurologic complications. The modi-
fied Fisher scale is designed to predict the development of delayed cerebral ischemia 
(DCI) which is the most common cause of disability secondary to rupture next the 
actual rupture itself (Tables 1–3).
4.3 Initial imaging
With such a large number of patients presenting to the ED with a chief com-
plaint of headache [79–84], the description of headache can help differentiating 
those with a benign cause from those with an emergent etiology such as SAH. The 
diagnosis of SAH should be considered in any patient with a severe and sudden 
onset or rapidly escalating headache (Figure 5).
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4.4 Management
Once the patient has been diagnosed with an SAH, treatment should focus on 
limiting secondary neurologic injuries to improve the patient’s functional outcome.
• Resuscitation of a patient with SAH should follow all established protocols 
with immediate attention to airway and circulatory support.
• After stabilization of the airway and circulation, treatments specific to SAH 
can begin.
4.5 Pharmacologic treatments
4.5.1 Antiepileptic drugs
In patients with a suspected ruptured aneurysm, seizures can lead to aneu-
rysmal rebleeding and result in intracranial hypertension and herniation, the 
Grade Criteria Survival
I Asymptomatic, mild headache, slight nuchal rigidity 70%
II Moderate to severe headache, nuchal rigidity, no neurological deficit other than 
cranial nerve palsy
60%
III Drowsiness/confusion and mild focal neurological deficit 50%
IV Stupor, moderate to severe hemiparesis 20%
V Coma, decerebrate positioning 10%
Table 2. 
Hunt and Hess scale.
Grade Appearance of blood on CT Risk of cerebral 
hemorrhage
0 No sub arachnoid hemorrhage (SAH) or ventricular hemorrhage 
(VH)
0%
1 Minimal SAH, No VH in 2 lateral ventricles 6%
2 Minimal SAH, VH in 2 lateral ventricles 14%
3 Large SAH, No VH in 2 lateral ventricles 12%
4 Large SAH, VH in 2 lateral ventricles 28%
Table 3. 
Modified fisher grading system [82].
Grade Glasgow coma scale (GCS) Neurological exam
1 15 No motor deficit
2 13–14 No motor deficit
3 13–14 Motor deficit
4 7–12 With/without motor deficit
5 5–6 With/without motor deficit
Table 1. 
World Federation of Neurological Surgeons Grading System for Subarachnoid Hemorrhage - (WFNS) scale.
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risk of being highest in patients with poor Hunt and Hess grade and those with 
thick subarachnoid blood [85]. Routine prophylactic antiepileptic drug use in 
patients with SAH is a common practice despite limited evidence The American 
Stroke Association (ASA) guideline recommends consideration of short-term 
prophylactic antiepileptic drug use in the immediate post hemorrhage period [86]. 
No randomized controlled trials have investigated the safety and effectiveness of 
antiepileptic drugs in SAH [87].
4.6 Nimodipine
Delayed cerebral ischemia (DCI) is one of the most serious complications associ-
ated with SAH, occurring in one-third of patients surviving the initial hemorrhage 
and results in poor outcome in half of the patients with this complication [86]. 
Nimodipine is a calcium antagonist that is thought to reduce the rate of cerebral 
vasospasm by reducing the influx of calcium into the vascular smooth muscle cells. 
The administration of nimodipine to reduce the risk of poor outcome and DCI is the 
only level IA evidence recommended by the ASA [86].
4.7 Blood pressure management
There is general consensus that hypertension should be controlled after SAH 
and until the ruptured aneurysm is secured. However, specific parameters for blood 
pressure have not been defined and data are sparse. Early retrospective studies sug-
gest a higher rate of rebleeding with SBP greater than 160 mm Hg and severity of 
initial hemorrhage [88]. Therefore, the ASA and Neurocritical Care Society recom-
mend maintaining SBP less than 160 mm Hg and mean arterial pressure less than 
110 mm Hg before the ruptured aneurysm is secured to reduce the risk of rebleed-
ing [86, 87, 89, 90]. The ideal antihypertensive to use in SAH would be a parenteral 
agent that produces a rapid and reproducible dose response while concurrently 
minimizing adverse cerebral effects. Labetalol, nicardipine, and clevidipine are 
agents recommended by the ASA [86].
Figure 5. 
Flowchart of management aSAH [1, 10–12].
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4.8 Antifibrinolytics
When early definitive treatment of the ruptured aneurysm is not possible, anti-
fibrinolytic therapies such as amino epsilon caproic acid or tranexamic acid can be 
considered to reduce the risk of early aneurysmal rebleeding. Early studies showed 
a reduction in rebleeding but an increase in cerebral ischemia with prolonged use 
of antifibrinolytics [88]. Neither aminocaproic acid or tranexamic acid is approved 
by the US Food and Drug Administration for prevention of aneurysmal rebleeding, 
thus the use of antifibrinolytic therapies should be discussed on a case-by-case 
basis.
4.9 Rebleeding
Rebleeding can occur before the ruptured aneurysm is secured, and is associ-
ated with significant mortality and poor prognosis for functional recovery, most 
common within the first 24 hours, with some studies reporting peak time of 
rebleeding within 2 hours [88]. Factors associated with rebleeding include longer 
time to aneurysm treatment, worse neurologic status on presentation, initial loss 
of consciousness, previous sentinel headaches, larger aneurysm size, and possibly 
SBP greater than 160 mm Hg [91]. Although early definitive treatment of ruptured 
aneurysms can reduce the risk of rebleeding, approximately 12–15% of patients die 
before reaching the hospital [90].
4.10 External ventricular drainage
Acute hydrocephalus is common in patients with SAH and is a common cause of 
early neurologic decline. Treatment of symptomatic hydrocephalus often requires 
placement of an external ventricular drain, which allows ICP monitoring as well as 
CSF drainage. Untreated hydrocephalus can lead to intracranial hypertension and 
cerebral ischemia with potential cerebral herniation. Identification of the presence 
of hydrocephalus on CT and communication of this finding with neurosurgical 
consultants are key steps in the management of SAH.
4.11 Microsurgical clipping versus endovascular coiling
Definitive treatment of SAH is early microsurgical clipping or endovascular 
coiling of the ruptured aneurysm to prevent rebleeding and its associated complica-
tions. Choice of treatment modality depends on aneurysm size, characteristics, 
and location, as well as the patient’s clinical grade and comorbidities [92]. The 
International Subarachnoid Aneurysm Trial (ISAT) [93] is a multicenter, random-
ized clinical trial, which compares a policy of neurosurgical clipping with a policy 
of endovascular treatment with detachable platinum coils in patients with ruptured 
intracranial aneurysms considered suitable for either treatment. The results show 
that endovascular intervention with detachable platinum coils in patients with 
ruptured intracranial aneurysms can improve the chances of independent survival 
compared with neurosurgical intervention to clip the neck of the aneurysm.
4.12 Pipeline embolization device
The PED has mostly been used to treat unruptured aneurysms, whereas its 
use for acutely ruptured aneurysms has been limited and is theoretically contra-
indicated, given the need for dual antiplatelet therapy as it increases the risk of 
re-hemorrhage [94].
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However, in certain cases of complex ruptured aneurysms, the PED may still 
serve as a good alternative (and sometimes may be the only available option) because 
these aneurysms are anatomically and technically more difficult to treat using 
standard techniques [93]. Furthermore, certain anticoagulation protocols can be 
put into place to prevent the feared consequences associated with PED placement in 
ruptured aneurysms due to dual antiplatelet therapy. The standard management for 
the prevention of thromboembolic events when using flow diverters is pretreatment 
with aspirin and clopidogrel for 7–10 days prior to the procedure. When treating 
ruptured aneurysms with the PED in conjunction with this dual antiplatelet therapy, 
there is a concern for hemorrhagic complications. Chalouhi and colleagues [95] 
described a new regimen for anticoagulation that was recently implemented in the 
hope of minimizing the risk of thromboembolic and hemorrhagic complications. In 
summary, the PED may be particularly helpful in acutely ruptured aneurysms that 
are not amenable to coiling or clipping. It can also be used in a staged fashion 1 or 
2 weeks after partial coiling of the aneurysm dome. It is generally preferable to place 
an external ventricular drain if treatment with the PED is contemplated [96].
5. Future directions
The future of neuroendovascular surgery is bright. The technology platforms 
for access, delivery and treatment continue to improve at exponential rates. As it 
is there has been a rapid change in the number of brain aneurysm patients treated 
with endovascular treatment versus open surgical clipping. With this change comes 
a great void in experience and skill in the open surgical management of brain aneu-
rysms. It remains to be seen whether this skill will be needed in the future [97].
5.1 Flow disruptor
Currently there is only one flow disruptor available in the US market; the WEB 
device. Currently, its limitations lie in the fact that it is only available in sizes to 
treat aneurysms 3–10 mm in size. The second limitation exists in its delivery system 
which, at larger sizes requires a 33-microcatheter, and at smallest sizes requires a 
21-microcatheter. As newer generations come to market over the next 5 years, we 
expect there to be improved deliverability, different shapes available, and smaller 
designs for smaller ruptured aneurysms [98].
5.2 Flow diverter
Currently there are two flow diverter stents available in the US Market, the 
Pipeline Flex (2nd generation), and the Surpass. Currently the bulk of innovation 
required with this technology is in finding a coating for the stent that might miti-
gate the need for dual anti-platelet therapy. The second area of innovation is in the 
deliverability of the stents, currently needing 27-microcatheter for delivery, there 
is an expectation that these stents can be delivered through a 21-microcatheter in 
the near future, with also smaller diameter stent sizes available to treat more distal 
aneurysms. We fully expect the indications on which type of aneurysms can be 
treated in the near future.
5.3 Endosaccular coiling
Coiling has likely reached its technological pinnacle. There has been little 
advancement in this technology over the last 5 years. One area of interest is in 
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endosaccular flow disruptor type coils such as the Medina system. This is not as 
of yet FDA approved and remains to be seen whether this is efficacious or safe. 
Also the adjunctive tools for coiling continue to improve such as the Atlas stent, 
Pulserider stent and barrel stent which all are improvements for the treatment 
of bifurcation aneurysms and make difficult to coil aneurysms easier. We expect 
further improvements in these designs, and with improvements in deliverability. 
In addition to stents, the balloons available for balloon assisted coiling continue to 
improve in shape, design and deliverability which are particularly helpful in the 
setting of a ruptured small or wide necked aneurysm [99].
5.4 Imaging and aneurysm rupture prediction
Currently other than aneurysm size, and certain bio-social risk factors, there is 
no way to accurately predict which aneurysms are at risk for rupture. Over the next 
5 years we expect to see, further advancement in the arena of MR vessel wall imag-
ing, and flow-modeling. We hope that this will help improve our predictive models.
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